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The study was to determine the appropriate dose and administration route 
of Ornitin Triple vaccine in cross-breed coloured broilers in Vietnam by 
evaluating the antibody titer against Ornithobacterium rhinotracheale 
(ORT) and local reactions at injection sites on chickens after vaccination. 
The study was divided into 2 trials. Both trials were designed with 3 vac-
cine dose groups: 0.0ml (control group), 0.25ml and 0.5ml and 2 different 
administration routes: subcutaneous at neck (SC) and intramuscular at 
breast (IM) injection. The result showed that, no statistically significant 
difference was found between antibody titer of two administration routes as 
well as 2 vaccine doses until 13-week-old. Local reactions at the injection 
sites of IM route was less severe than SC at neck and in higher dose would 
produce a more severe swelling reaction. Daily weight gain was found to 
have a slight decrease in the vaccinated groups within 2 weeks after vac-
cination, however, no statistically significant difference was found in later 
stage (P > 0.05). In conclusion, Ornitin Triple can be used to vaccinate by 
IM with the dose of 0.25ml for coloured broilers at early age (3-week-old), 
or 0.5ml for older birds and should be careful for some reactions at the in-
jection sites.
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1. Introduction
Respiratory diseases are the most common among the considerably difficult problems and account for a high proportion in poultry diseases. There 
are many different causes for respiratory diseases includ-
ing microorganism factors and farms’ management [8]. 
Among those, bacteria Ornithobacterium rhinotracheale 
(ORT) plays an important part in causing complex re-
spiratory syndromes with high mortality [15]. Diversity 
of ORT with 18 serotypes (type A to type R), serotype A 
was the most common with 94% [4,7]. Beside that, a survey 
on random samples, Numee et al found that 3 common 
serotypes were A (35.5%), B (19.4%), and C (12.9%) [11]. 
Unlike other repiratory causes, ORT was discovered rath-
er late; it was not known until 1981; the first case of ORT 
infection was found in turkeys in Germany [3]. Mortality 
rate of ORT was from 1% to 15% in chickens aged 2-8 
weeks old; however, in cases where ORT was followed 
by a sencondary infection, mortality rate could reach up 
to 50% [5]. Common clinical signs caused by ORT include 
coughing, nasal discharge, labored breathing, decreased 
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feed and water intake and could lead to death [9]. In breed-
ers, the disease could cause the flock to decrease its egg 
production as well as produce weak offsprings [5]. As ORT 
is a slow grower and require a really special growing en-
vironment, other bacteria (such as E.coli), which have the 
ability to grow fast and easily, would be dominant in the 
infected organs [12]. Moreover, ORT is usually a second-
ary infection to other diseases such as Infections bursal 
disease (IBD), Newcastle (ND) and Infectious Bronchitis 
(IB). These are all factors contributing to the late or mis-
diagnosis and hinder prevention of ORT infection and 
therefore would leave a negative impact on the economy. 
In 1998, according to John R. Glisson, treatment with 
antibiotics was more efficient than using vaccine [8]. How-
ever, one year later, Van Empel and Hafez (1999) found 
that treatment of ORT with antibiotics would be extremely 
difficult due to the fact that most ORT strains had already 
developed antibiotic resistance [16]. In 2001, Devries et al 
found that ORT bacteria strains were already resistant to 
80-100% of commonly used antibiotics in treating poultry, 
namely ampicillin, ceftiofur, tylosin, spiramycin, lincomy-
cin, tilmicosin, flumequine, enrofloxacin and doxycycline 
[6]. As a result, deeper research into ways to prevent the 
disease might be a more effective solution against ORT. 
Van Empel et al. (1999) carried on a study on the ORT 
vaccine with an oil adjuvant capable of reducing clinical 
signs of the disease. From that, this study carried on to 
evaluate the serum HGA and the reaction at the injection 
site of the chicken after vaccination [16]. In 2002, Cau-
werts et al conducted an experiment on vaccine against 
ORT in Belgium and brought about good results such as a 
decrease in mortality rate and an increase in poultry pro-
duction performance [2]. In 2005, Schuijffel et al proved 
the ability to generate cross protection against different 
serotypes of ORT [14]. However, bacterial vaccines are of-
ten seen causing strong reactions in poultry as well as the 
level of immune response largely depends on the reaction 
at the injection sites and vaccine antigen [13]. As a result, 
this research was the first in Vietnam to determine the 
appropriate doses, administration routes and age in order 
to simultaneouly minimize the side effects and be able to 
produce a high and prolonged antibody titer to protect lo-
cal cross-breed broilers from ORT.
2. Materials and Methods
2.1 Materials
Ornitin Triple (Phibro Animal Health, USA) is an oil 
emulsion vaccine. In the dose of 0.5ml, the antigen 
amount consists of 109 CFU for each serotype A, B and C. 
Vaccine is recommended to use in prevention of respirato-
ry diseases caused by ORT. Information of vaccine bottle 
was used in this study: the batch number: 24461034 and 
expiry date: 23-05-2020.
Cross-breed colored broilers chickens in Vietnam or 
namedly backyard chickens or native chickens are raised 
for 14-16 weeks, with live body weigh at slaughter time in 
average for 2 – 2.5 kg/bird.
2.2 Methods
2.2.1 Experimental Design
The research consisted of 2 trials:
Trial I: 108 3-week-old local cross-bred broilers 
Trial II: 120 5-week-old local cross-bred broilers 
All chickens in both trials were tagged individually on 
the legs. They were initially weighed, measured for ORT 
antibody before vaccinated and randomly allocated into 
six groups according to 2 factors shown in Table 1.
(1) 0.0ml represented control group, injected with 0.5ml 
saline solution (NaCl 0.9%). 
(2) 0.25ml represented test group injected with 0.25ml 
Ornitin Triple vaccine. 
(3) 0.5ml represented test group injected with 0.5ml 
Table 1. Experimental design
Trial I: ORT vaccination at 21 days old Trial II: ORT vaccination at 35 days old
Subcutaneous
(SC) Intramuscularly (IM)
Subcutaneous
(SC) Intramuscularly (IM)
Dose (ml)
Group 0.0 0.25 0.5 0.0 0.25 0.5 0.0 0.25 0.5 0.0 0.25 0.5
Bird/ cage 9 9 9 9 9 9 10 10 10 10 10 10
No. cage 2 2 2 2 2 2 2 2 2 2 2 2
Total bird 18 18 18 18 18 18 20 20 20 20 20 20
No. blood sample 10 10 10 10 10 10 10 10 10 10 10 10
Average BW (g/bird) 312.7 312.1 312.3 312.5 312.1 312.5 760.1 759.6 763.1 761.5 760.4 759.2
DOI: https://doi.org/10.30564/vsr.v1i2.1190
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Ornitin Triple vaccine. 
(4) SC represented subcutaneous injection at neck. 
(5) IM represented intramuscular injection at breast. 
Experimented chickens were weighed and put into 
groups in each trial. Blood samples were taken from 10 
chickens in each group.
2.2.2 Effects of Administration Routes, Doses and 
Age to ORT Antibody Titer 
In each experiment, a total of 18-20 chickens were num-
bered and 10 were randomly selected for serum sample. 
Those 10 chickens were recorded of their tag number for 
later reference. Until they reached the age of 13 weeks 
old, in both experiments, 5 serum samples were collected 
in each cage. There were 30 serum samples in each trial 
collected each collecting time. A total of 600 serum sam-
ples from both trials were taken during the study.
ORT antibody titer in chickens’ serum samples was 
tested using ELISA technique by IDEXX commercial 
kit, IDEXX ORT Ab Test, USA, product code 99-43600. 
According to the recommendation of the manufacturer, 
grouping of ORT antibody titer was shown in Table 2 and 
samples with titer ≤ 844 would be considered as negative, 
and samples with titer ≥ 844 would be considered as posi-
tive (IDEXX, USA).
2.2.3 Evaluation of the Safety of Ornitin Triple 
vaccine
The safety of the vaccine was evaluated by chickens’ 
general body reactions and local reactions at the injection 
sites after vaccination. Chickens’ general body reactions 
of each group were assessed by body temperature and 
feed intake. Body temperature of chickens was measured 
using Amrus thermometer from 4PM to 6PM on day 1, 
2, 4, 5, 6, 8, 10, 14 after vaccination. Each group’s feed 
intake was also recorded for 14 continuous days after 
vaccination. Chickens’ local reactions at the injection sites 
were observed and scored: no swelling = 0 point, swelling 
less than 1cm = 1 point, swelling from 1-2 cm = 2 points, 
and swelling more than 2 cm = 3 points.
2.2.4 Evaluation of Vaccine’s Effects to Chickens’ 
Performance 
Chickens were weighed and recorded individually; their 
daily average weight gain (DAWG) was calculated using 
the following formula: 
DAWG =
Weight after Weight before
Age after Age before
  ( )
  ( )
(
(
)
)
−
−
2.3 Experimental Data Analysis
Data was collected and managed by MS Excel 2010 (Mi-
crosoft, USA). Analyzed by T-student test for 2 group of 
trials, and  by ANOVA variance analysis method of soft-
ware R version 6.3.1. 
3. Results and Discussions
3.1 Evaluation of the Level of ORT Antibody Ti-
ter before and after Vaccination 
Before vaccination, ORT antibody titer of chickens from 
all groups were recorded as negative (titer ≤ 844). Accord-
ing to IDEXX, chickens that were not vaccinated against 
ORT and not infected with ORT by field strains would 
be considered as negative against ORT and therefore, be 
classified into group 0 (Figure 1, Figure 2) (Table 2).
The results of chickens’ ORT antibody titer 3 weeks 
after vaccination were displayed in Figure 1 and 2. There 
was a significant difference between vaccinated groups 
and the control group in terms of ORT antibody titer. In 
trial I, 3 weeks after vaccination (chickens reached the age 
of 6 weeks), their ORT antibody titers would be classified 
into group 8 and above, with the average titer belonging 
to group 13 or 14, equivalent to 19000 – 20000 titer unit. 
In trial II, 3 weeks after vaccination (chickens reached 
the age of 8 weeks), the lowest ORT antibody titer was 
recorded   at group 15 range with the average titer falling 
into group 16 or 17. In figure 1, titers ranged from group 8 
to 16 while in figure 2, titers ranged from group 15 to 18. 
This result showed that older chickens can produce higher 
Table 2. Grouping of ORT antibody titer (xChekPlus software, IDEXX, USA)
Grouping 0 1 2 3 4 5 6 7 8 9
Antibody titer 0-844 845-999
1000
-1999
2000
-2999
3000
-3999
4000
-4999
5000
-5999
6000
-7999
8000
-9999
10000
-11999
Grouping 10 11 12 13 14 15 16 17 18
Antibody titer 12000-13999
14000
-15999
16000
-17999
18000
-19999
20000
-21999
22000
-23999
24000
-27999
28000
-31999 ≥32000
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and more uniform ORT antibody titers 3 weeks after vac-
cination. 
Figure 1. Grouping of ORT antibody titer of chickens at 3 
weeks old (before vaccination) and 3 weeks after vaccina-
tion in Trial I
Figure 2. Grouping of ORT antibody titer of chickens at 5 
weeks old (before vaccination) and 3 weeks after vaccina-
tion in Trial II
3.2 ORT Antibody Titer Post Vaccination
Each group’s ORT antibody titers at different ages from 
trial I and II were recorded in Table 3 and 4, respective-
ly. Before vaccination, ORT antibody titers of all groups 
were similarly low and not significanly difference (P > 
0.05). After vaccination, both trials’ vaccinated groups 
experienced an increase in antibody titer compared to the 
control groups (P < 0.001). In addition, 2 weeks after vac-
cination, both trial I and trial II had ORT antibody titers 
surged significantly, while in control groups, all were in 
negative group (Table 3, Table 4).
3.2.1 Effects of Administration Routes to ORT 
Antibody Titer 
According to Bermudez (2008), vaccines needed to be 
administered at the correct sites in order to achieve the 
best immune response for poultry [1]. Different type of 
vaccine would require a different optimal injection site. 
The effects of administration routes were evaluated based 
on assessing groups with the same administration dose of 
each trial. In trial I, with the vaccine dose of 0.25 ml, ORT 
antibody titer of SC route was not different from that of 
IM route; similarly, there was no statistical significance 
between 2 administration routes with the vaccine dose 
of 0.5 ml (P > 0.05) (table 3). The same situation applied 
to trial II when assessing 2 administration routes with no 
difference found (P > 0.05) (table 4). It can be concluded 
that, SC or IM injection does not affect the ORT antibody 
titer of coloured broilers, as there was no significant dif-
ference found between the 2 injection routes. Although, 
there was no statistically difference between SC and IM, it 
should be carefully to use IM at breast route for broilers to 
be slaughtered less than 6 weeks after vaccination because 
IM injection will damage inside the muscle and leave con-
sequences on the carcass quality.
3.2.2 Effects of Vaccine Doses to ORT Antibody 
Titer
The effect of injection dose on the antibody titer was as-
Table 3. Effects of administration routes and doses to ORT antibody titer after vaccinating with Ornitin Triple vaccine – 
Trial I
Subcutaneous (SC) Intramuscularly (IM) F-value
P-value0.0 ml 0.25ml 0.5 ml 0.0 ml 0.25 ml 0.5 ml
3 weeks old
(N = 10)
X±SD
CV%
176.7
± 101.5
57.4
235.0
± 185.7
79
251.6
± 297.3
118.2
138.9
± 134.3
96.7
116.4
± 57.2
49.1
189.5
± 173.1
91.4
0.902
0.487
5 weeks old
(N = 10)
X±SD
CV%
113.4
± 182b
160.5
16269.5
± 493.9a
39.9
16081.1
± 416.6a
39.9
115.9
± 214.5b
185.1
14364.2
± 6408.3a
44.6
14343.0
± 6261.3a
43.7
22.679
0.000
6 weeks old
(N = 10)
X±SD
CV%
168.3
± 173.9b
103.3
19093.0
± 654.3a
24.4
18581.8
±4520.9a
24.3
187.9
± 246.2b
131
21182.5
± 4179.3a
19.7
18809.0
± 3667.5a
19.5
81.705
0.000
8 weeks old
(N = 10)
X±SD
CV%
192.7
± 247.6c
128.5
26537.8
± 85.7ab
11.6
27238.5
± 1762a
6.5
260.4
± 286.7c
110.1
22994.3
± 4875.7b
21.2
24741.4
± 4059.8ab
16.4
193.35
0.000
10 weeks old
(N = 5)
X±SD
CV%
995.6
± 558.1b
56.1
26365.2
± 248.9a
23.7
30085.2
± 831.7a
9.4
1360.6
± 520.4b
38.2
28194.5
± 7686.1a
27.3
32200.5
± 2424.5a
7.5
39.159
0.000
13 weeks old
(N = 5)
X±SD
CV%
571.2
± 443.2b
77.6
22692.8
± 8876a
39.1
25960.0
± 198.1a
8.5
767.4
± 504.8b
65.8
20615.4
± 7680.7a
37.3
25425.4
± 8390.4a
33
20.357
0.000
Note: abcMeans within a row with different superscripts differ (P < 0.05).
DOI: https://doi.org/10.30564/vsr.v1i2.1190
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sessed similarly to that of the injection routes. In trial I (Ta-
ble 3), there was no difference between the injection dose 
of 0.25 and 0.5 ml of the same SC or IM injection route (P> 
0.05). Trial II provided similar results to trial I (Table 4). 
It was clear from comparing results of both trials that the 
antibody titer of experimental chicken groups was not de-
pendant on the injection doses up to 13 weeks old (Table 3, 
Table 4). This results were obtained only until 13 weeks, it 
is possible that there is simply not sufficient time to reflect 
a long of immunity response to higher injection doses (0.5ml 
vs 0.25ml). Therefore, for chickens raising in longer than 
13 weeks, 0.5ml dose should be considered. 
3.2.3 Effects of Vaccination Age to ORT Antibody 
Titer 
The comparison of ORT antibody titer after vaccination 
between trial I and trial II was conducted by T test and the 
results were shown in Table 5. 
These 2 trials was conducted on chickens of 2 different 
age groups (Table 5), trial I used 3-week-old chickens and 
trial II used 5-week-old chickens. According to the results 
of comparing ORT antibody titers of these 2 trials, it was 
found that the antibody titer after vaccination with the 
vaccine dose of 0.25 ml in trial I was lower than that of 
trial II at the times of 2, 3 and 7 weeks after vaccination (P 
< 0.05). 
Likewise, at week 2 and 3 after vaccination with the 
vaccine dose of 0.5 ml, the ORT antibody titer of trial I 
was also lower than trial II (P < 0.001). However, after 
that and when the chickens reached the age of 13 weeks, 
no statistical difference was found between the trials (P > 
0.05). As a result, it could be concluded that with the same 
Table 4. Effects of administration routes and doses to ORT antibody titer after vaccinating with Ornitin Triple vaccine – 
Trial II
Subcutaneous (SC) Intramuscularly (IM) F-valueP-value
0.0 ml 0.25 ml 0.5 ml 0.0 ml 0.25 ml 0.5 ml
5 weeks old
(N = 10)
X±SD
CV%
198.9
± 186.8
93.94
177.0
± 132.3
74.73
197.0
± 207.6
105.38
155.8
± 88.0
56.44
196.9
± 96.7
49.13
201.9
± 80.5
39.85
0.164
0.975
7 weeks old
(N = 10)
X±SD
CV%
209.0
± 262.0b
125.34
25745.0 ± 
5957a
23.14
26458.0 ± 
6798a
25.69
270.1
± 295.8b
109.53
26125.0 ± 
5388a
20.62
26008.0
± 5290a
20.34
76.982
0.000
8 weeks old
(N = 10)
X±SD
CV%
224.7
± 244.4b
108.75
28669.0 ± 
2005a
6.99
29748.0 ± 
2364a
7.95
227.5
± 234.3b
102.99
27168.0 ± 
2767a
10.18
27985.0
± 2665a
9.52
520.28
0.000
10 weeks old
(N= 10)
X±SD
CV%
219.6
± 222.4c
24.41
24576.0 ± 
2501ab
10.18
27403.0 ± 
1609a
6.17
361.2
± 286.9c
79.43
23909.0 ± 
4467b
18.68
26746.0
± 1150ab
4.3
340.39
0.000
12 weeks old
(N = 5)
X±SD
CV%
1161.5
± 706.5b
60.8
39781.0 ± 
8101a
20.36
33063.0 ± 
10749a
32.51
821.0
± 425.0b
51.77
33788.0 
±10710a
31.70
38160.0
± 3462a
9.07
32.767
0.000
13 weeks old
(N = 5)
X±SD
CV%
632.0
± 233.0b
36.91
28182.0 ± 
5003a
17.75
25839.0
± 7878a
30.49
672.0
± 329.0b
49.00
24533.0 ± 
8752a
35.67
25827.0
± 3439a
13.32
24.829
0.000
Note: abMeans within a row with different superscripts differ (P < 0.05).
Table 5. Effects of vaccination age to ORT antibody titer
Dose of 0.25 ml
Df TP-value
Dose of 0.5 ml
Df tP-value21 Days old 35 Days old 21 Days old 35 Days old
Vaccination day 175.7 186.9 35.69 -0.27030.7885 220.6 199.5 32.37
0.3319
0.7421
2 weeks post 15316.9b 25935.2a 37.29 -5.63640.0000 15212.1
b 26232.9a 37.91 -5.72690.0000
3 weeks post 20137.8b 27918.5a 29.78 -6.84960.000 18695.4
b 28866.6a 32.68 -9.50630.0000
5 weeks post 24766.5 24242.6 36.44 0.41640.6794 25990.0 27074.5 26.02
-1.3446
0.1904
7 weeks post 21654.1b 36784.6a 17.43 -3.87380.0012 31142.9 35611.3 11.06
-1.6732
0.1223
13 weeks old* 20403.4 26560.0 16.95 -1.46360.1616 25692.7 25833.1 18.00
-0.0545
0.9571
Note: abMeans within a row with different superscripts differ (P < 0.05); *11 weeks post for Trial I & 8 weeks post for Trial II.
DOI: https://doi.org/10.30564/vsr.v1i2.1190
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vaccine doses, ORT antibody titer of 3-week-old chickes 
would increase at a slower rate compared to 5-week-old 
chickens; however, there would be no difference found 
between chickens of older age groups. 
0.0
5000.0
10000.0
15000.0
20000.0
25000.0
30000.0
35000.0
40000.0
Vaccination day 2 weeks post 3 weeks post 5 weeks post 7 weeks post 13 weeks old
An
tib
od
y 
tit
er
21 Days old - 0.25 ml 35 Days old - 0.25 ml 21 Days old - 0.5 ml 35 Days old - 0.5 ml
Figure 3. Effects of vaccination age and dose to ORT 
antibody titer
As recommended by vaccine manufacturer Ornitin 
Triple, the vaccine is suitable for turkeys 6 weeks of age 
and the appropriate vaccine dose is 0.5ml. However, 
there have been no specific recommendations for the 
local chicken breeds in Vietnam, which are raised for 
13-16 weeks (turkeys are 20 weeks or more) and were 
especially susceptible to ORT at 5-6 weeks of age (Vo et 
al, 2019).
The appropriate age for vaccination of chickens was in 
accordance with the body weight, the level of completion 
of the immune system, health status, disease pressures and 
especially the effects of bacterial vaccines which often 
caused a strong reaction in vaccinated chickens (Nguyen 
Ba Hien et al, 2007).
Figure 3 showed that if chickens can wait un-
til 5-week-old to be vaccinated would be better than 
3-week-old chickens. However, if ORT outbreak happen 
about 5-6 weeks of age then chickens should be vacci-
nated at least 2 weeks before that, which is 3-week-old. 
Figure 3 also showed that for chickens raised less than 
13 weeks, 0.25ml dose would be good enough, howev-
er, for chickens raised more than 13 weeks, 0.5ml dose 
should be considered. 
3.3 Vaccine Reaction
3.3.1 General Body Reactions of Chickens 
Body temperature
There was a fluctuation in body temperature after 
vaccination from day 5 of trial I and day 8 of trial II. 
There was a statistically significant difference between 
the control and vaccinated groups (P < 0.05). According 
to Nguyen Ba Hien et al, 2007, after vaccination, body 
temperature can increase by 0.5-1°C due to the immune 
responses that occur in the body. In this study, vaccination 
for younger chickens (3-week-old) would give a change in 
body temperature following the Ornitin Triple vaccination 
earlier (day 5 vs 8) than vaccination for older chickens 
(5-week-old) (Table 6, Table 7).
Table 6.  Effects of administration routes and doses to 
chickens’ body temperature – Trial I
Subcutaneous (SC) (oC)
P
F
Intramuscularly (IM) 
(oC) P
F
Dose 0.0 ml 0.25 ml 0.5ml 0.0ml 0.25ml 0.5ml
1 days 
post
40.9 ± 
0.4
41.1 ± 
0.3
41.1 ± 
0.3
0.086 
2.58
41 ± 
0.3
41.1 ± 
0.4
41.1 ± 
0.3
0.3445 
1.09
2 days 
post
41.3 ± 
0.3
41.4 ± 
0.2
41.4 ± 
0.3
0.3 
1.23
41.4 ± 
0.2
41.4 ± 
0.2
41.3 ± 
0.3
0.4756 
0.75
3 days 
post
41.1 ± 
0.2
41.2 ± 
0.3
41.3 ± 
0.4
0.071 
2.79
41.2 ± 
0.3
41.1 ± 
0.3
41.2 ± 
0.4
0.7590 
0.28
4 days 
post
41.3 ± 
0.2
41.3 ± 
0.3
41.5 ± 
0.3
0.108 
2.32
41.3 ± 
0.3
41.5 ± 
0.3
41.4 ± 
0.3
0.4105 
0.91
5 days 
post
41.1 ± 
0.4b
41.4 ± 
0.4ab
41.5 ± 
0.3a
0.013 
4.75
41.3 ± 
0.2b
41.5 ± 
0.3a
41.5 ± 
0.3ab
0.0398 
3.44
6 days 
post
41.1 ± 
0.3b
41.4 ± 
0.4a
41.3 ± 
0.4ab
0.035 
3.59
41.1 ± 
0.2
41.3 ± 
0.3
41.4 ± 
0.5
0.0642 
2.90
10 days 
post
41.7 ± 
0.3
41.7 ± 
0.3
41.7 ± 
0.3
0.735 
0.31
41.3 ± 
0.2b
41.7 ± 
0.3a
41.8 ± 
0.3a
0.0000 
14.58
Note: abMeans within a row with different superscripts differ (P < 0.05).
Table 7.  Effects of administration routes and doses to 
chickens’ body temperature – Trial II
Subcutaneous (SC) (oC) P
F
Intramuscularly (IM) 
(oC) P
F
Dose 0.0 ml 0.25 ml 0.5ml 0.0ml 0.25ml 0.5ml
1 days 
post
41.6 ± 
0.2
41.6 ± 
0.2
41.7 ± 
0.3
0.503 
0.70
41.5 ± 
0.2
41.6 ± 
0.2
41.6 ± 
0.2
0.141 
2.03
2 days 
post
41.6 ± 
0.2b
41.7 ± 
0.2ab
41.8 ± 
0.2a
0.005 
5.92
41.6 ± 
0.3
41.6 ± 
0.3
41.6 ± 
0.3
0.713 
0.34
4 days 
post
41.6 ± 
0.2
41.7 ± 
0.2
41.7 ± 
0.3
0.296 
1.24
41.6 ± 
0.3
41.7 ± 
0.2
41.6 ± 
0.3
0.580 
0.55
7 days 
post
41.5 ± 
0.2
41.5 ± 
0.3
41.6 ± 
0.2
0.084 
2.59
41.4 ± 
0.4
41.6 ± 
0.4
41.6 ± 
0.3
0.099 
2.40
8 days 
post
41.7 ± 
0.2
41.8 ± 
0.3
41.8 ± 
0.3
0.133 
2.09
41.7 ± 
0.2b
41.9 ± 
0.3a
41.8 ± 
0.2ab
0.029 
3.76
10 days 
post
41.5 ± 
0.2b
41.8 ± 
0.3a
42 ± 
0.3a
0.000 
14.15
41.5 ± 
0.2b
41.9 ± 
0.2a
41.8 ± 
0.3a
0.000 
11.85
14 days 
post
41.6 ± 
0.2
41.6 ± 
0.2
41.7 ± 
0.3
0.876 
0.13
41.6 ± 
0.2
41.7 ± 
0.3
41.8 ± 
0.3
0.051 
3.14
Note: abMeans within a row with different superscripts differ (P < 0.05).
Feed intake
The effects of the vaccination to chickens’ feed intake 
were evaluated in the same rearing environment in order 
to produce the most accurate result. The feed intake (g/
chicken/day) after vaccination of each group was recorded 
every 2-3 days. The results showed that the feed intake of 
chickens in both trials decreased after vaccination. How-
ever, around 3-4 weeks afterwards, no significant differ-
ence was found (table 8 and 9). 
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Table 8. Chickens’ daily feed intake after vaccination – 
Trial I
Days old
Subcutaneous (SC) (gam/bird/
day)
Intramuscularly (IM) (gam/
bird/day)
0.0ml 0.25 ml 0.5  ml 0.0 ml 0.25 ml 0.5 ml
35* - 37 65.6 64.2 62.2 68.2 73.0 63.6
38 - 40 72.6 67.8 65.9 69.6 74.9 67.1
41 - 43 79.4 56.9 63.3 83.8 68.3 66.2
44 - 47 89.4 69.6 53.9 85.7 71.4 71.8
48 - 50 90.2 79.3 79.1 95.1 78.0 75.7
51 - 53 91.8 90.8 94.2 93.9 90.5 82.2
Note: *vaccination time
Table 9. Chickens’ daily feed intake after vaccination – 
Trial II
Days old
Subcutaneous (SC) (gam/bird/
day)
Intramuscularly (IM) (gam/bird/
day)
0.0ml 0.25 ml 0.5  ml 0.0 ml 0.25 ml 0.5 ml
21* - 24 47.8 44.8 42.4 46.9 43.9 45.2
25 - 28 52.7 42.4 41.1 55.8 48.3 42.7
29 - 35 92.4 71.8 64.6 99.1 83.5 81.0
36 - 44 64.2 51.6 45.8 66.8 55.5 48.0
45- 49 73.0 67.6 59.2 75.9 63.4 62.5
50 - 52 98.4 95.6 89.4 92.3 89.5 94.5
Note: *vaccination time
3.3.2 Local Reactions at the Injection Sites
In the control groups, no reaction at the injection sites was 
recorded. In the vaccinated groups, swelling reaction start-
ed to increase 4-7 days after vaccination and peaked at 9-10 
days after vaccination. In both trials, swelling reaction was 
found to develop the strongest in vaccinated groups with 
the dose of 0.5 ml by SC at neck and then 0.25 ml by SC at 
neck (Figure 4, Figure 5). In general, in both trials, IM route 
would produce a less severe swelling reaction compared 
to SC route; and at some time, the swelling at the injection 
sites of chickens with the vaccine dose of 0.5 ml would be 
more severe than those with the dose of 0.25 ml.
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3.4 Growth Performance
The performance of chickens in each group was evaluated 
by their daily weight gain and the results were shown in 
Table 8 and 9. In both trials, within 2 weeks after vacci-
nation, the chickens’ performance had been influenced by 
the vaccine (P < 0.001), especially the SC-0.5ml group 
was most seriously affected.  However later on (up to 91 
days old), no difference was found between vaccinated 
groups and control groups (P > 0.05). 
A comparison between groups with the same adminis-
tration routes or the same vaccine doses was performed 
in order to compare the effects of administration routes or 
vaccine doses to the perfomance of chickens. 
In both trials, at the beginning of the first 2 weeks after 
vaccination, all vacination groups had a significant weight 
gain lower than the control groups (Table 10, Table 11). At 
the same time, the first 2 weeks of both experiments, SC 
groups with the vaccine dose of 0.5 ml was documented to 
have a significant lower weight gain than those with the IM 
group with the vaccine dose of 0.25 ml (P < 0.001) (Table 
10, Table 11). This could be the result of swelling reaction 
which was found to develop the strongest in vaccinated 
groups with the dose of 0.5 ml by SC at neck (Figure 4, 
Figure 5). The swelling reaction in the neck reduced feed 
intake especially during the first 2 weeks (Table 8, Table 9). 
Although, the vaccination groups did have an influence on 
chickens' performance at the beginning of both trials, how-
ever after two weeks, all vaccination groups recovered and 
no statistically significant influence on growth performance 
was documented (P> 0.05) (Table 10, Table 11).
4. Conclusion
In both trials, there was a development of ORT antibody 
titer by the 2 administration routes as well as with the 2 
vaccine doses. The increase in antibody titer was quite 
stable in the vaccinated groups, which was statistically 
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significant compared to the control group.
There was no antibody titer statistically difference 
found between the two administration routes with the 
same dose and age (P> 0.05). ORT antibody titer of 
vaccine doses were different at the beginning but no 
difference when chickens reached the age of 13 weeks. 
Chickens vaccinated at 3 weeks old had a slower immune 
response than 5-week-old chickens.
Reactions at the injection site began to fluctuate 5-8 
days after vaccination. The swelling reaction at the injec-
tion site by IM was less severe than SC route. Simulta-
neously, the smaller the vaccine dose, the less severe the 
swelling reaction.
Chicken growth index was affected 2-3 weeks after 
vaccination, however, no difference was found in later 
stages compared to the control group, which was reflected 
by feed intake and weight gain.
In conclusion, it was recommended that Ornitin Triple 
vaccine could be used for the young cross-breed coloured 
broilers in Vietnam at the dose of 0.25ml by IM or 0.5ml 
for older broilers which need to raise for more than 13 
weeks. Moreover, it was also necessary to pay attention to 
the reaction at the injection sites after vaccination.
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